SCHEMBL29392800

SCHEMBL29392800

N[C@@H](Cc1ccccc1)C(=O)C(=O)OCC1c2ccccc2-c2ccccc21

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ FABP5 Q01469 3/20 0.48
▸ FABP7 O15540 2/20 0.48
▸ ALPI P09923 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ PTGS1 P23219 1/20 0.46
▸ XIAP P98170 1/20 0.46
▸ SLC7A5 Q01650 1/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ CASP3 P42574 2/20 0.43
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ SLC15A1 P46059 1/20 0.41
▸ EPHX2 P34913 1/20 0.41
▸ ANPEP P15144 1/20 0.40
▸ RNPEP Q9H4A4 1/20 0.40
▸ DNPEP Q9ULA0 1/20 0.40
▸ LTA4H P09960 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16128286 1.00 FABP5 (0.48) FABP5FABP7ALPIPKMPTGS1
SCHEMBL16128284 0.91 KMT2A (0.46) FABP5FABP7SLC7A5KMT2ACASP3
SCHEMBL16128277 0.85 CASP3 (0.50) FABP5FABP7KMT2ACASP3CA1
SCHEMBL29823700 0.85 PPARG (0.39) FABP5FABP7KMT2ACASP3EPHX2
SCHEMBL29966663 0.84 KMT2A (0.51) FABP5FABP7KMT2ACASP3CA1
SCHEMBL15318692 0.84 KMT2A (0.51) FABP5FABP7KMT2ACASP3CA1
SCHEMBL15424391 0.83 KMT2A (0.50) FABP5FABP7KMT2ACASP3CA1
SCHEMBL14416228 0.83 KMT2A (0.47) FABP5FABP7KMT2ACASP3CA1
SCHEMBL29510568 0.83 KMT2A (0.47) FABP5FABP7KMT2ACASP3CA1
SCHEMBL15290535 0.82 CASP3 (0.45) FABP5FABP7KMT2ACASP3EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617819-B2 Intermediate used for biologically active polypeptide and method for preparing same HANMI FINE CHEMICAL CO., LTD. (KR) 2026-05-05 — — US disclosed
CN-115073555-A Method for synthesizing pasireotide 中国医学科学院药物研究所 2022-09-20 — — CN disclosed
US-20220242913-A1 NOVEL INTERMEDIATE USED FOR BIOLOGICALLY ACTIVE POLYPEPTIDE AND METHOD FOR PREPARING SAME HANMI FINE CHEMICAL CO., LTD. (KR) 2022-08-04 — — US disclosed
US-11255848-B2 Polymer-nanostructure composition for selective molecular recognition MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2022-02-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220242913-A1 NOVEL INTERMEDIATE USED FOR BIOLOGICALLY ACTIVE POLYPEPTIDE AND METHOD FOR PREPARING SAME VIP, IAPP, ANPEP FABP5 1686/4885FABP7 920/4885ALPI 386/4885
US-12617819-B2 Intermediate used for biologically active polypeptide and method for preparing same VIP, PTMS, HM13 FABP5 4405/4885FABP7 2486/4885ALPI 3320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback